Aydemir et al. examined the relationship between disease activity in rheumatoid arthritis (RA) and pain regulatory mechanisms of the central nervous system. They found that improvements in pain sensitivity were associated with reductions in disease activity in patients with RA after 12 weeks of treatment with disease-modifying anti-rheumatic drugs. This study underscores the importance of inflammatory and noninflammatory contributors to patient outcomes.
New EULAR/ACR criteria help stratify RA risk in patients with arthralgia. Learn how these criteria guide earlier interventions & improve trial rigor.
New studies reveal predictors for avoidable RA hospitalizations, PsA transition in psoriasis & the impact of neighborhood on childhood lupus.
Using data from registries across Europe and Canada, Aymon et al. compared the incidence of major adverse cardiac events (MACE) in patients with RA treated with JAK inhibitors, TNF inhibitors or biologic DMARDs with other modes of action over two years. The researchers did not find an increased risk of MACE with JAK inhibitors over that time frame.
Dr. Diane van der Woude reviewed provided a detailed review of the latest research on rheumatoid arthritis, addressing findings on disease prevention, supplements, novel treatments and much more.
A recent study in A&R identifies an association between air pollutants, including fire smoke particulate matter, & both rheumatoid arthritis (RA) & RA-associated interstitial lung disease.
Early study results demonstrate that rosnilimab may be safe and effective for patients with rheumatoid arthritis, reducing the signs and symptoms of RA by week 12 and achieving important primary and secondary study end points.
Risk of Mortality from SLE By Ansaam Daoud, MD, Loai Dweik, MD, & Omer Pamuk, MD Why was this study done? Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with significant mortality, particularly affecting racial and ethnic minorities. This study aimed to assess national SLE mortality trends over the past two decades, stratified by…
Patients with RA not only suffer from functional limitations, but also face increased healthcare costs, primarily due to prescription drug use, says Dr. Yinan Huang.
In this study, researchers set out to determine the prevalence of baseline risk factors for cardiovascular outcomes and cancer among commercially insured patients with rheumatoid arthritis during their first dispensed treatment.